amiodarone has been researched along with Cardiomyopathy, Hypertrophic in 97 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Cardiomyopathy, Hypertrophic: A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amiodarone reduces the incidence of atrial fibrillation (AF) following coronary artery bypass surgery; however, the benefit of perioperative amiodarone in patients undergoing septal myectomy (SM) for obstructive hypertrophic cardiomyopathy (oHCM) has not been studied." | 8.02 | Perioperative Amiodarone to Prevent Atrial fibrillation after Septal Myectomy in obstrUctive hypeRtroPHic cardiomyopathy. ( Akhavein, R; Al-Rashdan, L; Elman, MR; Fischer, KL; Heitner, SB; Lin, LQ; Mannello, M; Masri, A; Nazer, B; Shalen, EF; Song, HK, 2021) |
| "To describe the successful management of ventricular fibrillation (VF) and ventricular tachycardia (VT) using cardiopulmonary resuscitation, including defibrillation, followed by continuous rate infusion of IV amiodarone, in a cat with cardiac arrest secondary to tachyarrhythmia." | 7.96 | Successful management of ventricular fibrillation and ventricular tachycardia using defibrillation and intravenous amiodarone therapy in a cat. ( Berlin, N; Kelmer, E; Maiorkis, I; Ohad, DG, 2020) |
| "Neurologic toxicity is an infrequently reported and under-recognized consequence of amiodarone, symptoms of which may include tremor, peripheral sensorimotor neuropathy, proximal weakness, and ataxia." | 7.73 | Severe ataxia caused by amiodarone. ( Kligfield, P; Krauser, DG; Segal, AZ, 2005) |
| "We report a case of amiodarone-induced thyrotoxicosis, diagnosed with a systematic laboratory investigation in a 64-year-old patient, for haematuria." | 7.69 | [Amiodarone-induced thyrotoxicosis cured by thyroidectomy]. ( Guerin-Robardey, AM; Le Cosquer, P; Ossart, M, 1996) |
| "The values of two Holter ambulatory electrocardiographic monitoring criteria and one programmed stimulation efficacy criterion reported to be predictive of the efficacy of amiodarone were compared in 70 patients taking amiodarone for sustained ventricular tachyarrhythmias." | 7.67 | Comparison of programmed stimulation and Holter monitoring for predicting long-term efficacy and inefficacy of amiodarone used alone or in combination with a class 1A antiarrhythmic agent in patients with ventricular tachyarrhythmia. ( Felder, SD; Figura, I; Fisher, JD; Johnston, DR; Kim, SG; Waspe, LE, 1987) |
| "The effect of amiodarone on survival was assessed in patients with hypertrophic cardiomyopathy and ventricular tachycardia in a drug trial with historical controls." | 7.67 | Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. ( Goodwin, JF; Krikler, DM; McKenna, WJ; Oakley, CM, 1985) |
| "Amiodarone reduces the incidence of atrial fibrillation (AF) following coronary artery bypass surgery; however, the benefit of perioperative amiodarone in patients undergoing septal myectomy (SM) for obstructive hypertrophic cardiomyopathy (oHCM) has not been studied." | 4.02 | Perioperative Amiodarone to Prevent Atrial fibrillation after Septal Myectomy in obstrUctive hypeRtroPHic cardiomyopathy. ( Akhavein, R; Al-Rashdan, L; Elman, MR; Fischer, KL; Heitner, SB; Lin, LQ; Mannello, M; Masri, A; Nazer, B; Shalen, EF; Song, HK, 2021) |
| "To describe the successful management of ventricular fibrillation (VF) and ventricular tachycardia (VT) using cardiopulmonary resuscitation, including defibrillation, followed by continuous rate infusion of IV amiodarone, in a cat with cardiac arrest secondary to tachyarrhythmia." | 3.96 | Successful management of ventricular fibrillation and ventricular tachycardia using defibrillation and intravenous amiodarone therapy in a cat. ( Berlin, N; Kelmer, E; Maiorkis, I; Ohad, DG, 2020) |
| "Neurologic toxicity is an infrequently reported and under-recognized consequence of amiodarone, symptoms of which may include tremor, peripheral sensorimotor neuropathy, proximal weakness, and ataxia." | 3.73 | Severe ataxia caused by amiodarone. ( Kligfield, P; Krauser, DG; Segal, AZ, 2005) |
| "The aim of this study was to evaluate the survival of patients with hypertrophic cardiomyopathy (HCM) after resuscitated ventricular fibrillation or syncopal sustained ventricular tachycardia (VT/VF) when treated with low dose amiodarone or implantable cardioverter defibrillators (ICDs)." | 3.70 | Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. ( Elliott, PM; McKenna, WJ; Poloniecki, J; Rowland, E; Sharma, S; Varnava, A, 1999) |
| "We report a case of amiodarone-induced thyrotoxicosis, diagnosed with a systematic laboratory investigation in a 64-year-old patient, for haematuria." | 3.69 | [Amiodarone-induced thyrotoxicosis cured by thyroidectomy]. ( Guerin-Robardey, AM; Le Cosquer, P; Ossart, M, 1996) |
| "Fifty-three patients with hypertrophic cardiomyopathy who had serious arrhythmias (45 patients), refractory chest pain (5 patients) or a high risk of sudden death (3 patients) received amiodarone for 6 to 96 months (median 18) after completion of a loading and an initial maintenance period." | 3.67 | Amiodarone for long-term management of patients with hypertrophic cardiomyopathy. ( Goodwin, JF; Harris, L; Kleinebenne, A; Krikler, DM; McKenna, WJ; Oakley, CM; Rowland, E, 1984) |
| "The values of two Holter ambulatory electrocardiographic monitoring criteria and one programmed stimulation efficacy criterion reported to be predictive of the efficacy of amiodarone were compared in 70 patients taking amiodarone for sustained ventricular tachyarrhythmias." | 3.67 | Comparison of programmed stimulation and Holter monitoring for predicting long-term efficacy and inefficacy of amiodarone used alone or in combination with a class 1A antiarrhythmic agent in patients with ventricular tachyarrhythmia. ( Felder, SD; Figura, I; Fisher, JD; Johnston, DR; Kim, SG; Waspe, LE, 1987) |
| "The effect of amiodarone on survival was assessed in patients with hypertrophic cardiomyopathy and ventricular tachycardia in a drug trial with historical controls." | 3.67 | Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. ( Goodwin, JF; Krikler, DM; McKenna, WJ; Oakley, CM, 1985) |
| "Amiodarone has a more favourable therapeutic profile than flecainide and propafenone in these patients, having less tendency to worsen heart failure." | 2.67 | A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Antiarrhythmic Drug Evaluation Group (A.D.E.G.). ( , 1992) |
| "Of the 7 sudden deaths, 6 occurred within 5 months of initiation of treatment." | 2.67 | Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy. ( Bonow, RO; Cannon, RO; Epstein, SE; Fananapazir, L; Leon, MB; Tracy, CM, 1991) |
| "Hypertrophic cardiomyopathy is a genetic disease that affects the cardiac sarcomere, resulting in myocardial hypertrophy and disarray." | 2.43 | Sudden death and hypertrophic cardiomyopathy: a review. ( Dubuc, M; Greiss, I; Guerra, PG; Ly, HQ; Macle, L; Roy, D; Talakic, M; Thibault, B, 2005) |
| "The prevention of sudden death remains a key aspect of clinical management in patients with hypertrophic cardiomyopathy (HCM)." | 2.41 | The role of pharmacologic treatment to prevent sudden death in the implantable cardioverter defibrillator era. ( Elliott, PM, 2001) |
| "The role of arrhythmias in the pathogenesis of sudden cardiac death in hypertrophic cardiomyopathy is reviewed together with the role of programmed ventricular stimulation." | 2.39 | Risk assessment and prevention of sudden cardiac death in hypertrophic cardiomyopathy. ( Camm, AJ; Slade, AK, 1996) |
| "Amiodarone has been demonstrated to be an important and effective antiarrhythmic agent, as has sotalol." | 2.38 | Empiric use of amiodarone and sotalol. ( Nora, M; Zipes, DP, 1993) |
| "Amiodarone has also been reported to improve symptoms dramatically in some patients with HCM but to cause functional deterioration in others." | 2.38 | Effects of amiodarone on erect and supine exercise haemodynamics and exercise capacity in patients with hypertrophic cardiomyopathy. ( Counihan, PJ; Frenneaux, MP; Lipkin, DP; McKenna, WJ; Porter, A, 1992) |
| "This article discusses arrhythmias in hypertrophic and dilated cardiomyopathy in relation to clinical significance and treatment; when possible, the authors comment on etiology." | 2.37 | Arrhythmias in dilated and hypertrophic cardiomyopathy. ( Goodwin, JF; Krikler, DM; McKenna, WJ, 1984) |
| "Hypertrophic cardiomyopathy is a frequent cause of sudden death." | 1.42 | Implantable Cardioverter-defibrillator Therapy for Hypertrophic Cardiomyopathy: Usefulness in Primary and Secondary Prevention. ( Alcalde, Ó; Anguera, I; Galve, E; García-Dorado, D; Moya, À; Núñez, E; Sabaté, X; Sarrias, A; Villuendas, R, 2015) |
| "A 60-year-old man with polyarteritis nodosa under treatment presented with syncope." | 1.32 | Polyarteritis nodosa and hypertrophic obstructive cardiomyopathy. A true association? ( Moyssakis, I; Papadopoulos, DP; Votteas, VE, 2004) |
| "Amiodarone (200 mg/day) was continuously administered after DC shock to maintain SR." | 1.32 | Simultaneous double external DC shock technique for refractory atrial fibrillation in concomitant heart disease. ( Demircioglu, F; Ersel-Tüzüner, F; Kabukcu, M; Minareci, K; Yanik, E, 2004) |
| "We report cases of serious arrhythmias associated with apical hypertrophic cardiomyopathy (AHCM)." | 1.31 | Serious arrhythmias in patients with apical hypertrophic cardiomyopathy. ( Azegami, K; Itoh, K; Okishige, K; Sasano, T; Suzuki, K; Yano, K, 2001) |
| "Amiodarone has been reported to reduce the likelihood of sudden death in patients with hypertrophic cardiomyopathy (HCM)." | 1.30 | Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population. ( Cecchi, F; Dolara, A; Maron, BJ; Montereggi, A; Olivotto, I; Squillatini, G, 1998) |
| "Patients with hypertrophic cardiomyopathy are traditionally thought to have increased sympathetic activity." | 1.29 | Is there increased sympathetic activity in patients with hypertrophic cardiomyopathy? ( Camm, AJ; Fei, L; Malik, M; McKenna, WJ; Prasad, K; Slade, AK, 1995) |
| "Amiodarone abolished paroxysmal atrial arrhythmias in all 6 patients." | 1.28 | Value of electrophysiologic studies in hypertrophic cardiomyopathy treated with amiodarone. ( Epstein, SE; Fananapazir, L, 1991) |
| "Amiodarone therapy was associated with maintenance of sinus rhythm, fewer alterations in drug therapy, fewer embolic episodes and fewer attempted direct current cardioversions (during a shorter follow-up period)." | 1.28 | Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. ( Frenneaux, MP; Karatasakis, G; McKenna, WJ; Poloniecki, JD; Robinson, K; Stockins, B, 1990) |
| "In amiodarone-treated patients, the major findings were as follows: a 50% incidence of hepatic dysfunction with a tenfold increase in concentrations of serum glutamic-oxaloacetic transaminase and serum glutamic-pyruvic transaminase; a 25% incidence of pulmonary dysfunction necessitating a fourfold increase in the number of days of ventilator support; and a 19% incidence of low cardiac output syndrome with two deaths." | 1.28 | Amiodarone-induced complications after cardiac operation for obstructive hypertrophic cardiomyopathy. ( Clark, RE; Kupferschmid, JP; Leon, MB; McIntosh, CL; Rosengart, TK, 1989) |
| "Non-sustained ventricular tachycardia occurs in 20% of patients and is the single best predictor of sudden death in adults." | 1.28 | Arrhythmia and hypertrophic cardiomyopathy. ( Keeling, PJ; McKenna, WJ; Shakespeare, CF; Slade, AK, 1992) |
| "He was found to have incessant ventricular tachycardia, impaired left ventricular contraction (ejection fraction 9%), and nonobstructive hypertrophic cardiomyopathy." | 1.28 | Suppression of incessant ventricular tachycardia in hypertrophic cardiomyopathy associated with improvement of severe left ventricular dysfunction. ( Fananapazir, L; McAreavey, D, 1992) |
| "The mechanisms underlying the cause of sudden death have not been clearly elucidated." | 1.27 | [Arrhythmias in hypertrophic cardiomyopathy. Significance and therapeutic consequences]. ( Kleinebenne, A; McKenna, WJ, 1985) |
| "65 patients with dilated cardiomyopathy underwent 24-hour electrocardiographic monitoring: 95." | 1.27 | [Ambulatory ECG in cardiomyopathies]. ( Camerini, F; Di Lenarda, A; Mestroni, L; Miani, D; Neri, R, 1987) |
| "Ventricular tachycardia is detected during electrocardiographic monitoring in 20 to 30% of patients; this arrhythmia is a sensitive but non-specific marker of those patients who are at particular risk of sudden death." | 1.27 | Arrhythmia and prognosis in hypertrophic cardiomyopathy. ( McKenna, WJ, 1983) |
| "Hypertrophic cardiomyopathy is a cardiac disorder of unknown aetiology which is characterised by hypertrophy of a non-dilated left ventricle." | 1.27 | Does treatment influence the natural history of patients with hypertrophic cardiomyopathy? ( McKenna, WJ, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 29 (29.90) | 18.7374 |
| 1990's | 37 (38.14) | 18.2507 |
| 2000's | 18 (18.56) | 29.6817 |
| 2010's | 9 (9.28) | 24.3611 |
| 2020's | 4 (4.12) | 2.80 |
| Authors | Studies |
|---|---|
| Shalen, EF | 1 |
| Heitner, SB | 1 |
| Al-Rashdan, L | 1 |
| Akhavein, R | 1 |
| Elman, MR | 1 |
| Fischer, KL | 1 |
| Lin, LQ | 1 |
| Mannello, M | 1 |
| Nazer, B | 1 |
| Song, HK | 1 |
| Masri, A | 1 |
| Hagino, M | 1 |
| Ota, C | 1 |
| Onoki, T | 1 |
| Iwasawa, S | 1 |
| Arunachalam, K | 1 |
| Maan, A | 1 |
| Chu, A | 1 |
| Berlin, N | 1 |
| Ohad, DG | 1 |
| Maiorkis, I | 1 |
| Kelmer, E | 1 |
| Levin, MD | 1 |
| Saitta, SC | 1 |
| Gripp, KW | 1 |
| Wenger, TL | 1 |
| Ganesh, J | 1 |
| Kalish, JM | 1 |
| Epstein, MR | 1 |
| Smith, R | 1 |
| Czosek, RJ | 1 |
| Ware, SM | 1 |
| Goldenberg, P | 1 |
| Myers, A | 1 |
| Chatfield, KC | 1 |
| Gillespie, MJ | 1 |
| Zackai, EH | 1 |
| Lin, AE | 1 |
| Spina, R | 1 |
| Granger, E | 1 |
| Walker, B | 1 |
| Subbiah, RN | 1 |
| Sarrias, A | 1 |
| Galve, E | 1 |
| Sabaté, X | 1 |
| Moya, À | 1 |
| Anguera, I | 1 |
| Núñez, E | 1 |
| Villuendas, R | 1 |
| Alcalde, Ó | 1 |
| García-Dorado, D | 1 |
| Cannavà, G | 1 |
| Currò, A | 1 |
| Pizoń, T | 1 |
| Rajzer, M | 1 |
| Wojciechowska, W | 1 |
| Jastrzebski, M | 1 |
| Olszanecka, A | 1 |
| Rojek, M | 1 |
| Jurczyszyn, A | 1 |
| Czarnecka, D | 1 |
| Kurt, IH | 1 |
| Yigit, T | 1 |
| Karademir, BM | 1 |
| Shimada, YJ | 1 |
| Sato, K | 1 |
| Hanon, S | 1 |
| Schweitzer, P | 1 |
| Pokorney, SD | 1 |
| Stone, NJ | 1 |
| Passman, R | 1 |
| Oyer, D | 1 |
| Rigolin, VH | 1 |
| Bonow, RO | 2 |
| Stellpflug, SJ | 1 |
| Fritzlar, SJ | 1 |
| Cole, JB | 1 |
| Engebretsen, KM | 1 |
| Holger, JS | 1 |
| Schamroth, CL | 1 |
| Nanda, S | 1 |
| Levin, V | 1 |
| Martinez, MW | 1 |
| Favale, S | 1 |
| Pappone, C | 1 |
| Nacci, F | 1 |
| Fino, F | 1 |
| Resta, F | 1 |
| Dicandia, CD | 1 |
| Seggewiss, H | 1 |
| Rigopoulos, A | 1 |
| Papadopoulos, DP | 1 |
| Moyssakis, I | 1 |
| Votteas, VE | 1 |
| Kabukcu, M | 1 |
| Demircioglu, F | 1 |
| Yanik, E | 1 |
| Minareci, K | 1 |
| Ersel-Tüzüner, F | 1 |
| Ly, HQ | 1 |
| Greiss, I | 1 |
| Talakic, M | 1 |
| Guerra, PG | 1 |
| Macle, L | 1 |
| Thibault, B | 1 |
| Dubuc, M | 1 |
| Roy, D | 1 |
| Krauser, DG | 1 |
| Segal, AZ | 1 |
| Kligfield, P | 1 |
| Zhou, L | 1 |
| Jiang, B | 1 |
| Li, HX | 1 |
| Chen, T | 1 |
| Cheng, XJ | 1 |
| Jiang, WP | 1 |
| Kashyap, AS | 1 |
| Anand, KP | 1 |
| Kashyap, S | 1 |
| Elliott, PM | 3 |
| Gimeno, JR | 1 |
| Tomé, MT | 1 |
| Shah, J | 1 |
| Ward, D | 1 |
| Thaman, R | 1 |
| Mogensen, J | 1 |
| McKenna, WJ | 19 |
| Cheng, MF | 1 |
| Wu, YW | 1 |
| Liu, YB | 1 |
| Huang, PJ | 1 |
| Tzen, KY | 1 |
| Yen, RF | 1 |
| Melacini, P | 2 |
| Maron, BJ | 4 |
| Bobbo, F | 1 |
| Basso, C | 1 |
| Tokajuk, B | 1 |
| Zucchetto, M | 1 |
| Thiene, G | 1 |
| Iliceto, S | 1 |
| Krikler, DM | 4 |
| Goodwin, JF | 7 |
| Harris, L | 3 |
| Rowland, E | 3 |
| Kleinebenne, A | 2 |
| Oakley, CM | 5 |
| Sugrue, DD | 1 |
| Dickie, S | 1 |
| Myers, MJ | 1 |
| Lavender, JP | 1 |
| Ovsyshcher, IA | 1 |
| Zimlichman, R | 1 |
| Perez, G | 1 |
| Oakley, C | 1 |
| Southworth, W | 1 |
| Friday, KJ | 1 |
| Ruffy, R | 1 |
| Desnos, M | 1 |
| Hagège, A | 1 |
| Guérot, C | 1 |
| Cardim, N | 1 |
| Longo, S | 1 |
| Gouveia, D | 1 |
| Lousada, N | 1 |
| Ferreira, T | 1 |
| Pereira, AT | 1 |
| Correia, JM | 1 |
| Fei, L | 2 |
| Slade, AK | 4 |
| Prasad, K | 2 |
| Malik, M | 2 |
| Camm, AJ | 3 |
| Heric, B | 1 |
| Lytle, BW | 1 |
| Miller, DP | 1 |
| Rosenkranz, ER | 1 |
| Lever, HM | 1 |
| Cosgrove, DM | 1 |
| Tascón, JC | 1 |
| Albarrán, A | 1 |
| Andreu, J | 1 |
| Alonso, M | 1 |
| Moro Serrano, C | 1 |
| Hernández Madrid, A | 1 |
| Lage Silveira, J | 1 |
| Vivas Alvarez, E | 1 |
| Kanjhi, M | 1 |
| Schwartz, J | 1 |
| Rafael, C | 1 |
| Rozenfeld, V | 1 |
| Abu-Much, Z | 1 |
| Schoham, H | 1 |
| Grace, AA | 1 |
| Delahaye, JP | 1 |
| Azzano, O | 1 |
| Albanesi Filho, FM | 1 |
| Girardi, JM | 1 |
| Castier, MB | 1 |
| Ginefra, P | 1 |
| Buja, G | 1 |
| Miorelli, M | 1 |
| Turrini, P | 1 |
| Nava, A | 1 |
| Nora, M | 1 |
| Zipes, DP | 1 |
| Almendral, JM | 1 |
| Ormaetxe, J | 1 |
| Martínez-Alday, JD | 1 |
| Villacastin, JP | 1 |
| Arenal, A | 1 |
| Pastor, A | 1 |
| Medina, O | 1 |
| Peinado, R | 1 |
| Delcan, JL | 1 |
| Rapezzi, C | 3 |
| Spirito, P | 1 |
| Alessandrini, RS | 1 |
| McPherson, DD | 1 |
| Kadish, AH | 1 |
| Kane, BJ | 1 |
| Goldberger, JJ | 1 |
| Le Cosquer, P | 1 |
| Guerin-Robardey, AM | 1 |
| Ossart, M | 1 |
| Cecchi, F | 2 |
| Montereggi, A | 2 |
| Olivotto, I | 2 |
| Marconi, P | 1 |
| Dolara, A | 2 |
| Duffee, DF | 1 |
| Shen, WK | 1 |
| Smith, HC | 1 |
| Frenneaux, MP | 3 |
| Squillatini, G | 1 |
| Sharma, S | 1 |
| Varnava, A | 1 |
| Poloniecki, J | 1 |
| Suwa, M | 1 |
| Cattaneo, F | 1 |
| Okishige, K | 1 |
| Sasano, T | 1 |
| Yano, K | 1 |
| Azegami, K | 1 |
| Suzuki, K | 1 |
| Itoh, K | 1 |
| Boriani, G | 1 |
| Biffi, M | 1 |
| Branzi, A | 2 |
| Duport, G | 1 |
| Valeix, B | 1 |
| Lefevre, J | 1 |
| Nebunu, JC | 1 |
| Bouteau, JM | 1 |
| Garcia-Duport, M | 1 |
| Chabrillat, Y | 1 |
| Swan, JH | 1 |
| Chisholm, AW | 1 |
| McAreavey, D | 1 |
| Fananapazir, L | 3 |
| Shakespeare, CF | 1 |
| Keeling, PJ | 1 |
| Hartmann, A | 1 |
| Kaltenbach, M | 1 |
| Hopf, R | 1 |
| Dritsas, A | 1 |
| Gilligan, D | 1 |
| Nihoyannopoulos, P | 1 |
| Gavaliatsis, IP | 1 |
| Kouvousis, NM | 1 |
| Rallidis, LS | 1 |
| Pirros, JM | 1 |
| Dionisopoulou, CT | 1 |
| Kremastinos, DT | 1 |
| Tsitouris, GK | 1 |
| Counihan, PJ | 2 |
| Porter, A | 1 |
| Lipkin, DP | 1 |
| Gilligan, DM | 1 |
| Missouris, CG | 1 |
| Boyd, MJ | 1 |
| Leon, MB | 2 |
| Tracy, CM | 1 |
| Cannon, RO | 1 |
| Epstein, SE | 2 |
| Campbell, RW | 1 |
| Robinson, K | 1 |
| Stockins, B | 1 |
| Karatasakis, G | 1 |
| Poloniecki, JD | 1 |
| Greenspan, AM | 1 |
| Kenny, D | 1 |
| Mercereau, D | 1 |
| Kubac, G | 1 |
| Klinke, WP | 1 |
| Kupferschmid, JP | 1 |
| Rosengart, TK | 1 |
| McIntosh, CL | 1 |
| Clark, RE | 1 |
| Orie, JE | 1 |
| Liedtke, AJ | 1 |
| Mulrow, JP | 1 |
| Holt, DW | 1 |
| Benenati, PM | 1 |
| Binetti, G | 1 |
| Piovaccari, G | 1 |
| Bacchi, M | 1 |
| Roncuzzi, R | 1 |
| Zannoli, R | 1 |
| Magnani, B | 1 |
| Leor, J | 1 |
| Levartowsky, D | 1 |
| Sharon, C | 1 |
| Farfel, Z | 1 |
| Mestroni, L | 1 |
| Miani, D | 1 |
| Neri, R | 1 |
| Di Lenarda, A | 1 |
| Camerini, F | 1 |
| Depelchin, P | 1 |
| Schoenfeld, P | 1 |
| Stoupel, E | 1 |
| Degré, S | 1 |
| Liberatore, MA | 1 |
| Low, RB | 1 |
| Enia, F | 1 |
| Comparato, C | 1 |
| Di Franco, F | 1 |
| Ledda, A | 1 |
| Mizio, G | 1 |
| Kim, SG | 1 |
| Felder, SD | 1 |
| Figura, I | 1 |
| Johnston, DR | 1 |
| Waspe, LE | 1 |
| Fisher, JD | 1 |
| Crick, JC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double Sequence External Defibrillation: A Randomized Controlled Trial in Patients With Atrial Fibrillation Refractory to DC Cardioversion[NCT03827915] | 100 participants (Anticipated) | Interventional | 2019-01-21 | Recruiting | |||
| A Randomized Prospective Comparison of DDD Chamber Pacing and Percutaneous Transluminal Septal Ablation in Obstructive Hypertrophic Cardiomyopathy Associated With Severe Drug-Refractory Symptoms[NCT00001894] | Phase 2 | 70 participants | Interventional | 1999-08-31 | Completed | ||
| Reversal of Cardiomyopathy by Suppression of Frequent Premature Ventricular Complexes - A Prospective Randomized Clinical Trial[NCT01566344] | 70 participants (Anticipated) | Interventional | 2012-05-31 | Recruiting | |||
| EvaLuation Using Cardiac Insertable Devices And TelephonE in Hypertrophic CardioMyopathy[NCT03259113] | 30 participants (Anticipated) | Interventional | 2017-08-16 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
20 reviews available for amiodarone and Cardiomyopathy, Hypertrophic
| Article | Year |
|---|---|
Atrial Fibrillation in Hypertrophic Cardiomyopathy: Evidence-based Review About Mechanism, Complications and Management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathy | 2020 |
Management of hypertrophic cardiomyopathy in children.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium Chann | 2003 |
Sudden death and hypertrophic cardiomyopathy: a review.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Death, Sudden, Cardiac; Defibrilla | 2005 |
Arrhythmias in dilated and hypertrophic cardiomyopathy.
Topics: Amiodarone; Arrhythmias, Cardiac; Cardiomegaly; Cardiomyopathy, Hypertrophic; Death, Sudden; Electro | 1984 |
The natural history of hypertrophic cardiomyopathy.
Topics: Amiodarone; Arrhythmias, Cardiac; Cardiomyopathy, Hypertrophic; Death, Sudden; Humans; Nifedipine; P | 1981 |
[Sudden death in hypertrophic myocardiopathy].
Topics: Amiodarone; Cardiomyopathy, Hypertrophic; Death, Sudden, Cardiac; Heart; Humans; Risk Factors | 1995 |
[Early surgical treatment of symptomatic hypertrophic obstructive myocardiopathy. Arguments against].
Topics: Adrenergic beta-Antagonists; Amiodarone; Cardiac Pacing, Artificial; Cardiomyopathy, Hypertrophic; D | 1995 |
[Amiodarone in the nineties: to whom and what dosage?].
Topics: Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Clinical Trials | 1995 |
Hypertrophic cardiomyopathy.
Topics: Adolescent; Adult; Age Factors; Aged; Amiodarone; Cardiac Pacing, Artificial; Cardiomyopathy, Hypert | 1993 |
[Hypertrophic obstructive cardiomyopathy: current treatment, indications and results].
Topics: Adrenergic beta-Antagonists; Amiodarone; Calcium Channel Blockers; Cardiac Pacing, Artificial; Cardi | 1994 |
Empiric use of amiodarone and sotalol.
Topics: Amiodarone; Cardiomyopathy, Hypertrophic; Coronary Disease; Death, Sudden, Cardiac; Heart Diseases; | 1993 |
Treatment of ventricular arrhythmias in patients with hypertrophic cardiomyopathy.
Topics: Amiodarone; Cardiomyopathy, Hypertrophic; Defibrillators, Implantable; Humans; Tachycardia, Ventricu | 1993 |
Risk assessment and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Cardiomyopathy | 1996 |
[Medical treatment for cardiomyopathies].
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 2000 |
The role of pharmacologic treatment to prevent sudden death in the implantable cardioverter defibrillator era.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Death, Sudden; Defibrillators, Imp | 2001 |
[Drug therapy of hypertrophic cardiomyopathy].
Topics: Adrenergic beta-Antagonists; Amiodarone; Calcium Channel Blockers; Cardiomyopathy, Hypertrophic; Hea | 1992 |
Effects of amiodarone on erect and supine exercise haemodynamics and exercise capacity in patients with hypertrophic cardiomyopathy.
Topics: Adult; Aged; Amiodarone; Cardiomegaly; Cardiomyopathy, Hypertrophic; Exercise; Exercise Test; Female | 1992 |
Is drug treatment of tachyarrhythmias a science or a lottery?
Topics: Amiodarone; Cardiomyopathy, Hypertrophic; Flecainide; Humans; Propafenone; Tachycardia | 1990 |
Low-dose amiodarone for the treatment of arrhythmias in hypertrophic cardiomyopathy.
Topics: Adolescent; Adult; Amiodarone; Arrhythmias, Cardiac; Cardiomyopathy, Hypertrophic; Humans; Middle Ag | 1989 |
[Amiodarone, a class 3 antiarrhythmic agent: current electrophysiological and therapeutic aspects].
Topics: Administration, Oral; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Cardiomyopathy, Hypertrophic; H | 1986 |
3 trials available for amiodarone and Cardiomyopathy, Hypertrophic
| Article | Year |
|---|---|
A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Antiarrhythmic Drug Evaluation Group (A.D.E.G.).
Topics: Amiodarone; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic; Dose-Response Relationship, Drug; | 1992 |
Amiodarone reduces QT dispersion in patients with hypertrophic cardiomyopathy.
Topics: Adolescent; Adult; Aged; Amiodarone; Cardiomyopathy, Hypertrophic; Echocardiography; Electrocardiogr | 1992 |
Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy.
Topics: Adult; Amiodarone; Cardiomyopathy, Hypertrophic; Death, Sudden; Electrocardiography, Ambulatory; Fem | 1991 |
74 other studies available for amiodarone and Cardiomyopathy, Hypertrophic
| Article | Year |
|---|---|
Perioperative Amiodarone to Prevent Atrial fibrillation after Septal Myectomy in obstrUctive hypeRtroPHic cardiomyopathy.
Topics: Amiodarone; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Coronary Artery Bypass; Humans; Lengt | 2021 |
Male infant with Noonan syndrome with
Topics: Amiodarone; Arrhythmias, Cardiac; Cardiomyopathy, Hypertrophic; Flecainide; Heart Failure; Humans; I | 2022 |
Successful management of ventricular fibrillation and ventricular tachycardia using defibrillation and intravenous amiodarone therapy in a cat.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Cardiopulmonary Resuscita | 2020 |
Nonreentrant atrial tachycardia occurs independently of hypertrophic cardiomyopathy in RASopathy patients.
Topics: Amiodarone; Arrhythmias, Cardiac; Calcium; Cardiomyopathy, Hypertrophic; Costello Syndrome; Digoxin; | 2018 |
Ventricular tachycardia in hypertrophic cardiomyopathy with apical aneurysm successfully treated with left ventricular aneurysmectomy and cryoablation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Cryosurgery; Diabetes Mellitus, Ty | 2013 |
Implantable Cardioverter-defibrillator Therapy for Hypertrophic Cardiomyopathy: Usefulness in Primary and Secondary Prevention.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Calcium Ch | 2015 |
Ventricular tachycardia associated with mid-ventricular obstructive hypertrophic cardiomyopathy and apical aneurysm.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Aneurysm; Anti-Arrhythmia Agents; Cardiomyopathy, Hyp | 2015 |
[Hypertrophic cardiomyopathy with midventricular obstruction of the left ventricle (MVO)--case report].
Topics: Aged; Amiodarone; Cardiomyopathy, Hypertrophic; Defibrillators, Implantable; Female; Heart Ventricle | 2015 |
Atrial fibrillation due to late amiodarone-induced thyrotoxicosis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Humans; Male; | 2008 |
Termination of recurrent ventricular tachycardia by continuous positive airway pressure ventilation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiomyopathy, H | 2009 |
Effect of amiodarone-induced hyperthyroidism on left ventricular outflow obstruction after septal myectomy for hypertrophic cardiomyopathy.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedu | 2010 |
Cardiotoxic overdose treated with intravenous fat emulsion and high-dose insulin in the setting of hypertrophic cardiomyopathy.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Amiodarone; Cardiomyopathy, Hypertrophic; Cardiotoxin | 2011 |
The perils of pharmacological treatment for obesity: a case of sibutramine-associated cardiomyopathy and malignant arrhythmias.
Topics: Amiodarone; Anti-Arrhythmia Agents; Appetite Depressants; Cardiomyopathy, Hypertrophic; Cyclobutanes | 2012 |
Ventricular tachycardia in "end stage" hypertrophic cardiomyopathy: a role of dronedarone.
Topics: Adult; Amiodarone; Cardiomyopathy, Hypertrophic; Dronedarone; Humans; Male; Tachycardia, Ventricular | 2012 |
Sudden death due to atrial fibrillation in hypertrophic cardiomyopathy: a predictable event in a young patient.
Topics: Adult; Amiodarone; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Death, Sudden, Cardiac; Defibr | 2003 |
Polyarteritis nodosa and hypertrophic obstructive cardiomyopathy. A true association?
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Cyclophosphamide; Drug Therapy, Co | 2004 |
Simultaneous double external DC shock technique for refractory atrial fibrillation in concomitant heart disease.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathy, Dilated; Cardiomyopat | 2004 |
Severe ataxia caused by amiodarone.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Ataxia; Atrial Fibrillation; Cardiomyopathy, | 2005 |
[The acute electrophysiological effects of amiodarone on normal and hypertrophied rat myocytes].
Topics: Amiodarone; Animals; Cardiomyopathy, Hypertrophic; Disease Models, Animal; Ion Channels; Myocytes, C | 2006 |
Severe ataxia caused by amiodarone.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Ataxia; Atrial Fibrillation; Cardiomyopathy, | 2006 |
Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Cardiomyopathy, Hypertrophic; Death, Sudden, | 2006 |
Extensive scar myocardium in hypertrophic cardiomyopathy with severe myocardial bridge.
Topics: Adult; Amiodarone; Cardiomyopathy, Hypertrophic; Cicatrix, Hypertrophic; Combined Modality Therapy; | 2007 |
Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyop | 2007 |
Amiodarone for long-term management of patients with hypertrophic cardiomyopathy.
Topics: Adolescent; Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Benzofurans; Cardiom | 1984 |
Effect of amiodarone on left ventricular ejection and filling in hypertrophic cardiomyopathy as assessed by radionuclide angiography.
Topics: Adolescent; Adult; Aged; Amiodarone; Benzofurans; Blood Pressure; Cardiac Output; Cardiomyopathy, Hy | 1984 |
Infective endocarditis in hypertrophic cardiomyopathy secondary to amiodarone treatment.
Topics: Amiodarone; Benzofurans; Cardiomyopathy, Hypertrophic; Endocarditis, Bacterial; Humans; Male; Middle | 1983 |
Medical and surgical treatment of hypertrophic cardiomyopathy.
Topics: Adolescent; Adult; Aged; Amiodarone; Cardiomyopathy, Hypertrophic; Child; Electric Countershock; Fem | 1983 |
Arrhythmia and prognosis in hypertrophic cardiomyopathy.
Topics: Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Death, Sudden; | 1983 |
Arrhythmia in hypertrophic cardiomyopathy. II: Comparison of amiodarone and verapamil in treatment.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Cardiomyopathy, Hypertrophic; Female; Hu | 1981 |
Possible amiodarone-aprindine interaction.
Topics: Adult; Amiodarone; Aortic Valve Insufficiency; Aprindine; Benzofurans; Cardiomyopathy, Hypertrophic; | 1982 |
[Hypertrophic cardiomyopathy: place and limitations of medical therapy].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Bradycardia; Calcium Channel Blocke | 1995 |
Is there increased sympathetic activity in patients with hypertrophic cardiomyopathy?
Topics: Adolescent; Adult; Amiodarone; Cardiomyopathy, Hypertrophic; Case-Control Studies; Circadian Rhythm; | 1995 |
Surgical management of hypertrophic obstructive cardiomyopathy. Early and late results.
Topics: Aged; Aged, 80 and over; Amiodarone; Cardiomyopathy, Hypertrophic; Chi-Square Distribution; Coronary | 1995 |
Change of the degree of septal hypertrophy in hypertrophic obstructive cardiomyopathy under procainamide treatment. A case report.
Topics: Aged; Aged, 80 and over; Amiodarone; Bradycardia; Cardiomyopathy, Hypertrophic; Contraindications; E | 1995 |
Ambulatory assessment of the QT interval in patients with hypertrophic cardiomyopathy: risk stratification and effect of low dose amiodarone.
Topics: Adult; Amiodarone; Cardiomyopathy, Hypertrophic; Death, Sudden, Cardiac; Electrocardiography; Humans | 1994 |
[Influence of atrial fibrillation in the natural history of hypertrophic cardiomyopathy].
Topics: Adolescent; Adult; Aged; Ambulatory Care; Amiodarone; Atrial Fibrillation; Cardiomyopathy, Hypertrop | 1994 |
Ventricular ectopic beats and non-sustained ventricular tachycardia.
Topics: Amiodarone; Arrhythmias, Cardiac; Cardiomyopathy, Hypertrophic; Humans | 1993 |
Comparison of QT dispersion in hypertrophic cardiomyopathy between patients with and without ventricular arrhythmias and sudden death.
Topics: Adolescent; Adult; Amiodarone; Cardiomyopathy, Hypertrophic; Child; Death, Sudden, Cardiac; Electroc | 1993 |
[Therapy of arrhythmias in hypertrophic cardiomyopathy].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiomy | 1995 |
Cardiac memory: a mechanical and electrical phenomenon.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atenolol; Cardiomyopathy, Hypertrophic; | 1997 |
[Amiodarone-induced thyrotoxicosis cured by thyroidectomy].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Cardiomyopathy, Hypertrophic; Humans; Male; Midd | 1996 |
Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy assessed by signal averaged P wave duration.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathy, Hy | 1997 |
Suppression of frequent premature ventricular contractions and improvement of left ventricular function in patients with presumed idiopathic dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 1998 |
Hypertrophic cardiomyopathy: is there a role for amiodarone?
Topics: Adolescent; Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Death, Sudden, | 1998 |
Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Death, Sudden, Cardia | 1998 |
Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy.
Topics: Adolescent; Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Child; Death, S | 1999 |
Type II amiodarone-induced thyrotoxicosis and concomitant papillary cancer of the thyroid.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Carcinoma, Papillary; Cardiomyopathy, | 2000 |
Serious arrhythmias in patients with apical hypertrophic cardiomyopathy.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmi | 2001 |
Hypertrophic cardiomyopathy with massive hypertrophy, amiodarone treatment and high defibrillation threshold at cardioverter-defibrillator implant.
Topics: Adult; Amiodarone; Cardiomyopathy, Hypertrophic; Combined Modality Therapy; Defibrillators, Implanta | 2002 |
[Importance of permanent right ventricular stimulation in obstructive cardiomyopathy].
Topics: Amiodarone; Cardiac Pacing, Artificial; Cardiomyopathy, Hypertrophic; Heart Ventricles; Humans; Male | 1978 |
Control of recurrent supraventricular tachycardia with amiodarone hydrochloride.
Topics: Amiodarone; Anti-Arrhythmia Agents; Benzofurans; Cardiomyopathy, Hypertrophic; Chronic Disease; Elec | 1976 |
Suppression of incessant ventricular tachycardia in hypertrophic cardiomyopathy associated with improvement of severe left ventricular dysfunction.
Topics: Adult; Amiodarone; Cardiomyopathy, Hypertrophic; Electrocardiography; Humans; Male; Pacemaker, Artif | 1992 |
Arrhythmia and hypertrophic cardiomyopathy.
Topics: Amiodarone; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Death, Sudden, Cardiac; Digoxin; Elec | 1992 |
Recurrent atrial flutter in apical hypertrophic cardiomyopathy.
Topics: Amiodarone; Atrial Flutter; Cardiac Pacing, Artificial; Cardiomyopathy, Hypertrophic; Echocardiograp | 1992 |
Sudden death due to ventricular tachycardia during amiodarone therapy in familial hypertrophic cardiomyopathy.
Topics: Amiodarone; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Death, Sudden; Electrocardiography, A | 1991 |
Value of electrophysiologic studies in hypertrophic cardiomyopathy treated with amiodarone.
Topics: Amiodarone; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Cardiomyopathy, Hypertrophic; Death, S | 1991 |
Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study.
Topics: Adolescent; Adult; Aged; Amiodarone; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Child; Cinea | 1990 |
Hypertrophic cardiomyopathy and atrial fibrillation: a change of perspective.
Topics: Amiodarone; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Humans; Survival Rate | 1990 |
Amiodarone prophylaxis in hypertrophic obstructive cardiomyopathy.
Topics: Amiodarone; Cardiomyopathy, Hypertrophic; Humans; Tachycardia | 1989 |
[Arrhythmias in hypertrophic cardiomyopathy. Significance and therapeutic consequences].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Complexes, Pr | 1985 |
Failure of amiodarone to prevent ventricular fibrillation (sudden death) in hypertrophic cardiomyopathy.
Topics: Adult; Amiodarone; Cardiomyopathy, Hypertrophic; Death, Sudden; Exercise Test; Humans; Male; Ventric | 1989 |
Amiodarone-induced complications after cardiac operation for obstructive hypertrophic cardiomyopathy.
Topics: Adult; Amiodarone; Arrhythmias, Cardiac; Cardiac Output, Low; Cardiomyopathy, Hypertrophic; Chemical | 1989 |
Cardiomyopathy. 2. Hypertrophic and restrictive/obliterative types.
Topics: Adrenergic beta-Antagonists; Amiodarone; Calcium Channel Blockers; Cardiomyopathy, Hypertrophic; Car | 1986 |
Amiodarone dose titration: a method to minimise side effects during long term therapy.
Topics: Amiodarone; Benzofurans; Cardiomyopathy, Hypertrophic; Humans; Long-Term Care; Photosensitivity Diso | 1986 |
Amiodarone and the cardiomyopathies.
Topics: Adult; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Cardiomyopathies; Cardiomyopathy, Dilated; Car | 1986 |
Haemodynamic effects of short term intravenous amiodarone for hypertrophic cardiomyopathy.
Topics: Adult; Amiodarone; Cardiomyopathy, Hypertrophic; Female; Hemodynamics; Humans; Infusions, Intravenou | 1988 |
Amiodarone and beta-adrenergic blockers: an interaction with metoprolol but not with atenolol.
Topics: Amiodarone; Atenolol; Bradycardia; Cardiomyopathy, Hypertrophic; Drug Interactions; Drug Therapy, Co | 1988 |
[Ambulatory ECG in cardiomyopathies].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomyopathies; Cardiomyopathy, Dilated; | 1987 |
Intravenous amiodarone for malignant dysrhythmias of hypertrophic cardiomyopathy.
Topics: Adolescent; Amiodarone; Arrhythmias, Cardiac; Cardiomyopathy, Hypertrophic; Humans; Injections, Intr | 1987 |
Systolic anterior motion of the mitral valve in patients with hypertrophic cardiomyopathy. Disappearance after treatment with amiodarone.
Topics: Adult; Amiodarone; Cardiomyopathy, Hypertrophic; Electrocardiography; Female; Follow-Up Studies; Hum | 1987 |
Comparison of programmed stimulation and Holter monitoring for predicting long-term efficacy and inefficacy of amiodarone used alone or in combination with a class 1A antiarrhythmic agent in patients with ventricular tachyarrhythmia.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Cardiomyopathy, Hypertrophic; | 1987 |
Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia.
Topics: Amiodarone; Benzofurans; Cardiomyopathy, Hypertrophic; Electrocardiography; Female; Heart Ventricles | 1985 |
Does treatment influence the natural history of patients with hypertrophic cardiomyopathy?
Topics: Amiodarone; Cardiomyopathy, Hypertrophic; Humans; Tachycardia | 1985 |
Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia.
Topics: Amiodarone; Benzofurans; Cardiomyopathy, Hypertrophic; Humans; Tachycardia | 1985 |